Palliative radiotherapy in addition to self-expanding metal stent for improving dysphagia and survival in advanced oesophageal cancer: Radiotherapy after Oesophageal Cancer Stenting (ROCS) study

Velindre NHS Trust (UK)0 个研究点目标入组 220 人开始时间: 2012年7月10日最近更新: 2023年3月13日

适应症

试验速览

2014 Protocol article in http://www.ncbi.nlm.nih.gov/pubmed/25336193 protocol 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/33610215/ results (added 22/02/2021) 2021 Results article in https://pubmed.ncbi.nlm.nih.gov/34042566/ (added 28/05/2021)

•1. Histological confirmation of oesophageal carcinoma excluding small cell histology
•2. Not suitable for radical treatment (oesophagectomy or radical chemoradiotherapy) either because of patient choice or medical reasons
•3. Dysphagia clinically assessed as needing stent as primary treatment of the dysphagia
•4. Age 16 years or over
•5. Discussion and treatment decision for SEMS placement made by an Upper GI multi-disciplinary team
•6. Clinician assessment of ability to attend for radiotherapy
•7. Expected survival of at least 12 weeks
•8. Written informed consent

•1. Histology of small cell carcinoma type
•2. Tumour length of greater than 12 cm
•3. Tumour growth within 2 cm of the upper oesophageal sphincter
•4. Endoscopic treatment of the tumour, other than dilatation, planned in the peri-stent period
•5. Presence of a tracheo-oesophageal fistula
•6. Presence of a pacemaker
•7. Previous radiotherapy to the area of the proposed radiotherapy field
•8. Planned endoscopic treatment of the tumour (e.g. laser) in the immediate peri-stenting period
•9. Pregnancy

发起方

Velindre NHS Trust (UK)